Published in Curr Opin Organ Transplant on August 01, 2011
Macrochimerism in Intestinal Transplantation: Association With Lower Rejection Rates and Multivisceral Transplants, Without GVHD. Am J Transplant (2015) 0.79
Survival of neural progenitors allografted into the CNS of immunocompetent recipients is highly dependent on transplantation site. Cell Transplant (2013) 0.79
A modern Cosmas and Damian: Sir Roy Calne and Thomas Starzl receive the 2012 Lasker~Debakey Clinical Medical Research Award. J Clin Invest (2012) 0.76
Human leucocyte antigen-defined microchimerism early post-transplant does not predict for stable lung allograft function. Clin Exp Immunol (2013) 0.75
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest (2010) 3.41
Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med (1978) 2.52
Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation (1991) 2.32
Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int (2010) 2.28
Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 2.16
Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation (2002) 1.86
Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery (1976) 1.84
Microchimerism and rejection in clinical transplantation. Lancet (1997) 1.53
Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood (1994) 1.49
Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation (2000) 1.45
Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg (1980) 1.45
Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation (2002) 1.42
Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation (1995) 1.32
Transplant tolerance in non-human primates: progress, current challenges and unmet needs. Am J Transplant (2006) 1.27
Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation (2010) 1.25
CD4+CD25+ regulatory T cells do not significantly contribute to direct pathway hyporesponsiveness in stable renal transplant patients. J Am Soc Nephrol (2003) 1.23
Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc (1970) 1.22
Enhanced survival of canine renal allografts of ALS- treated dogs given bone marrow. Transplant Proc (1973) 1.20
Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation (1994) 1.16
Donor-type microchimerism associated with graft rejection eight years after liver transplantation. N Engl J Med (1994) 1.13
Migration patterns of dendritic leukocytes. Implications for transplantation. Transplantation (1990) 1.13
Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation (2002) 1.11
Chimerism and tolerance in transplantation. Proc Natl Acad Sci U S A (2004) 1.07
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation (1998) 1.05
Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation (2001) 1.03
The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest (1997) 1.02
Persistence of donor lymphocytes in liver allograft recipients. Transplantation (1993) 1.02
Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation (1998) 1.01
Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol (2003) 0.95
An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation (1996) 0.94
Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation (2011) 0.93
Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses. Transplantation (2000) 0.93
High dose DBMC associated tolerance in live-related renal allograft recipients. Transplant Proc (2000) 0.93
Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol (2005) 0.93
Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant (2006) 0.93
Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl (2010) 0.93
Microchimerism and rejection: a meta-analysis. Clin Transplant (2000) 0.91
Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol (2010) 0.91
Long-term follow-up of donor chimerism and tolerance after human liver transplantation. Liver Transpl (2009) 0.90
The human bone marrow as an immunoregulatory organ. Transplantation (1999) 0.90
FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation (2007) 0.88
Involvement of multiple subpopulations of human bone marrow cells in the regulation of allogeneic cellular immune responses. Transplantation (2000) 0.88
Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ann N Y Acad Sci (1995) 0.88
Donor bone marrow infusion in deceased and living donor renal transplantation. Yonsei Med J (2004) 0.88
Solid organ transplant-associated acute graft-versus-host disease. Arch Pathol Lab Med (2010) 0.88
Modulatory effects of human donor bone marrow cells on allogeneic cellular immune responses. Transplantation (1997) 0.87
Cellular immune responses of human cadaver donor bone marrow cells and their susceptibility to commonly used immunosuppressive drugs in transplantation. Transplantation (1998) 0.85
Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol (1999) 0.85
Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation (2010) 0.84
Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation. J Immunol (2007) 0.84
Analysis of post-transplant immune status in recipients of liver/bone marrow allografts. Hum Immunol (1999) 0.83
Blood group chimerism. Curr Opin Hematol (2006) 0.83
Peripheral blood microchimerism in human liver and renal transplant recipients: rejection despite donor-specific chimerism. Transplantation (1997) 0.83
Functional CD25(bright+) alloresponsive T cells in fully immunosuppressed renal allograft recipients. Clin Transplant (2007) 0.83
Recent advances in quantitative chimerism analysis. Expert Rev Mol Diagn (2009) 0.82
Functional analysis of CD4+ CD25bright T cells in kidney transplant patients: improving suppression of donor-directed responses after transplantation. Clin Transplant (2008) 0.82
Simultaneous detection of X and Y chromosomes by two-colour fluorescence in situ hybridization in combination with immunophenotyping of single cells to document chimaerism after sex-mismatched bone marrow transplantation. Bone Marrow Transplant (1998) 0.82
Transplantation tolerance across major histocompatibility barriers after total lymphoid irradiation. Transplantation (1979) 0.82
Immunoregulatory role of chimerism in clinical organ transplantation. Bone Marrow Transplant (2001) 0.82
Microchimerism and renal transplantation: doubt still persists. Transplant Proc (2007) 0.81
Donor specific bone marrow cells suppress lymphocyte reactivity to donor antigens and differentially modulate TH1 and TH2 cytokine gene expression in the responder cell population. Transpl Immunol (1995) 0.80
Mega dose unfractionated donor bone marrow-derived cell infusion in thymus and periphery-an integrated clinical approach for tolerance in living related renal allografts. Transplant Proc (2003) 0.80
In vitro immunogenicity of cadaver donor bone marrow cells used for the induction of allograft acceptance in clinical transplantation. Transplantation (1999) 0.80
Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipients. Transplantation (1997) 0.79
Peripheral blood chimerism following human liver transplantation. Hepatology (1997) 0.79
Chimerism in peripheral blood of sensitized patients waiting for renal transplantation: clinical implications. Transplantation (2000) 0.79
Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism? Curr Opin Cardiol (1999) 0.78
A simultaneous negative and positive selection method that can detect chimerism at a frequency of 1 per 10,000 by flow cytometry. Tissue Antigens (1997) 0.78
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation. Blood (2000) 0.78
Donor human leukocyte antigens in the circulation of liver allograft recipients. Clin Transplant (1995) 0.76
Chimerism and thoracic organ transplantation. Semin Thorac Cardiovasc Surg (1996) 0.76
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant (2003) 1.64
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging (2010) 1.56
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation (2013) 1.50
Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol (2006) 1.50
Heterogeneity of cognitive trajectories in diverse older persons. Psychol Aging (2010) 1.44
Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation (2002) 1.42
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation (2002) 1.32
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 1.32
Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. Am J Transplant (2005) 1.29
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 1.28
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol (2007) 1.26
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation (2005) 1.25
Proposed classification of complications after live donor nephrectomy. Urology (2006) 1.15
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation (2007) 1.13
Allosensitization of islet allograft recipients. Transplantation (2007) 1.13
Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation (2002) 1.11
Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res (2006) 1.06
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
Pretransplant evaluation of renal transplant candidates. Semin Nephrol (2002) 1.03
Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Transplantation (2006) 1.02
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation (2007) 1.01
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant (2005) 1.01
Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation (2005) 1.00
The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 0.99
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation (2004) 0.99
Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans. Transplantation (2013) 0.98
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation (2004) 0.96
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation (2015) 0.96
The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation (2013) 0.95
Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol (2003) 0.95
Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94
A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation (2004) 0.94
The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation (2010) 0.93
Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation (2011) 0.93
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation (2003) 0.93
Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol (2004) 0.92
Use of older controlled non-heart-beating donors for liver transplantation. Transplantation (2003) 0.92
Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation. Exp Cell Res (2008) 0.92
Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation (2008) 0.92
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant (2008) 0.91
Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol (2009) 0.91
Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol (2010) 0.91
Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Hum Immunol (2011) 0.89
Sequential kidney/islet transplantation using prednisone-free immunosuppression. Am J Transplant (2002) 0.89
FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation (2007) 0.88
Laparoscopic living donor nephrectomy: a single-center sequential experience comparing hand-assisted versus standard technique. Urology (2007) 0.88
Donor bone marrow infusion in deceased and living donor renal transplantation. Yonsei Med J (2004) 0.88
Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation (2002) 0.88
Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow. Hum Immunol (2004) 0.87
HLA-DQ barrier: effects on cPRA calculations. Transplantation (2013) 0.87
Epitope analysis of HLA-DQ antigens: what does the antibody see? Transplantation (2014) 0.86
Donor bone marrow transplantation: chimerism and tolerance. Transpl Immunol (2004) 0.86
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation (2006) 0.86
Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation (2007) 0.85
Hypercoagulable state associated with kidney-pancreas transplantation. Thromboelastogram-directed anti-coagulation and implications for future therapy. Clin Transplant (2004) 0.83
Inhibition of NF-kappa B during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches. Hum Immunol (2007) 0.83
Vascular complications of pancreas transplantation. Pancreas (2004) 0.82
The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. Am J Transplant (2003) 0.81
A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation (2002) 0.81
Viral interleukin-10-engineered autologous hematopoietic stem cell therapy: a novel gene therapy approach to prevent graft rejection. Hum Gene Ther (2004) 0.81
Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol (2012) 0.81
Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. Am J Transplant (2005) 0.81
Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. Transplantation (2015) 0.81
Plasma homocysteine and risk of mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 0.80
Ureteral complications in the era of laparoscopic living donor nephrectomy: do we need to preserve the gonadal vein with the specimen? J Endourol (2010) 0.80
Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation (2007) 0.80
A novel approach to detect donor/recipent immune responses between HLA-identical pairs. Hum Immunol (2006) 0.80
Role of innate and acquired immune mechanisms in clinical intestinal transplant rejection. Transplantation (2015) 0.79
Campath-1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up. Transplantation (2008) 0.79
The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants. Clin Transplant (2003) 0.79
A novel micro-cell-mediated lympholytic assay for the evaluation of regulatory cells in human alloreactive CTL responses. J Immunol Methods (2003) 0.79
Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells. PLoS One (2011) 0.79
Technical and immunologic progress in simultaneous pancreas-kidney transplantation. Surgery (2002) 0.79
Detection of HLA and MICA antibodies before kidney graft failure. Clin Transpl (2006) 0.78
Requirement of cognate CD4+ T-cell recognition for the regulation of allospecific CTL by human CD4+ CD127- CD25+ FOXP3+ cells generated in MLR. PLoS One (2011) 0.78
Functional and phenotypic properties of peripheral T cells anergized by autologous CD3(+) depleted bone marrow cells. Hum Immunol (2002) 0.78
Host-derived enterocytes in intestinal grafts. Transplantation (2002) 0.78
Simultaneous pancreas-kidney transplantation in Jehovah's Witness patients. Clin Transplant (2003) 0.78
Effect of glucose toxicity on intraportal tilapia islet xenotransplantation in nude mice. Xenotransplantation (2005) 0.78
Underreporting of psychopathology on the MMPI-2: a meta-analytic review. Psychol Assess (2002) 0.78
HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance. Clin Transpl (2013) 0.78
Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: the Northwestern University experience. Transplantation (2008) 0.77
Campath-1H does not alter bone marrow cell regulatory function. Hum Immunol (2005) 0.77
Facilitating cells in tolerance induction for kidney transplantation. Curr Opin Organ Transplant (2015) 0.77
Locomotor and resistance training restore walking in an elderly person with a chronic incomplete spinal cord injury. NeuroRehabilitation (2010) 0.77
Diabetic muscle infarction after simultaneous pancreas-kidney transplant. Clin Transplant (2002) 0.76
Piscine islet xenotransplantation. ILAR J (2004) 0.76
Induction of auto-reactive regulatory T cells by stimulation with immature autologous dendritic cells. Immunol Invest (2007) 0.76
Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant (2004) 0.76
Expression of MUC2 and MUC4 proteins and cytokines: early markers of intestinal graft rejection. Transplantation (2003) 0.75
Evaluation of the tolerogenic effects of donor bone marrow cells using a severe combined immunodeficient mouse-human islet transplant model. Hum Immunol (2008) 0.75
Induction therapy in renal transplantation : an overview of current developments. Drugs (2007) 0.75
A simple technique for aortic cannulation in organ donors with advanced aortic disease. Prog Transplant (2002) 0.75
Utilization of dried blood spot citrulline level as a noninvasive method for monitoring graft function following intestinal transplantation. Transplantation (2005) 0.75